Please login to the form below

Not currently logged in
Email:
Password:

Onconova appoints Ajay Bansal as chief financial officer

He joins from Complete Genomics

Ajay Bansal Onconova TherapeuticsAjay Bansal has left Complete Genomics to join cancer specialists Onconova Therapeutics as chief financial officer and president

Bansal (pictured) served as chief financial officer at Complete Genomics since May 2010, having previously held the role of chief financial officer and executive VP of business development at Lexicon Therapeutics.

He joins US-based Onconova as the company prepares to complete enrolment for a phase III study to investigate lead drug candidate rigosertib in patients with myelodysplastic syndromes.

“The potential benefit of rigosertib for the treatment of patients with both solid and haematological malignancies presents a significant opportunity, and I look forward to helping the company meet its objectives for this compound and the rest of the pipeline,” said Bansal.

In addition to his prior roles at Complete Genomics and Lexicon, Bansal has also served as chief financial officer at Nektar Therapuetics and Tercica, later acquired by Ipsen.

8th April 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Cannes or Canned
Creating a culture where innovation thrives
It starts with us...
David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...

Infographics